このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Titan Pharmaceuticals マネジメント

マネジメント基準チェック /04

現在、CEO に関する十分な情報がありません。

主要情報

David Lazar

最高経営責任者

US$1.5m

報酬総額

CEO給与比率	27.6%
CEO在任期間	2.2yrs
CEOの所有権	0.5%
経営陣の平均在職期間	データなし
取締役会の平均在任期間	2.2yrs

経営陣の近況

Recent updates

CEO報酬分析

Titan Pharmaceuticals の収益と比較して、David Lazar の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Jun 30 2024	n/a	n/a	-US$5m
Mar 31 2024	n/a	n/a	-US$5m
Dec 31 2023	US$1m	US$406k	-US$6m
Sep 30 2023	n/a	n/a	-US$6m
Jun 30 2023	n/a	n/a	-US$8m
Mar 31 2023	n/a	n/a	-US$9m
Dec 31 2022	US$726k	US$152k	-US$10m

報酬と市場: Davidの総報酬 ($USD 1.47M ) は、 US市場 ($USD 680.27K ) の同規模の企業の平均を上回っています。

報酬と収益: Davidの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

David Lazar (33 yo)

2.2yrs

在職期間

US$1,473,180

報酬

Mr. David Elliot Lazar had been Chief Business Development Officer of TRACON Pharmaceuticals, Inc. from May 7, 2024 until June 19, 2024. He was Chairman and CEO of OpGen, Inc. from March 25, 2024 Until Aug...

取締役

名称	ポジション	在職期間	報酬	所有権
Katherine Beebe-DeVarney	President	4.8yrs	US$602.11k	0.36% $ 17.7k
David Natan	Independent Director	2.2yrs	US$251.16k	0.36% $ 17.6k
Matthew McMurdo	Independent Director	2.2yrs	US$239.07k	0.36% $ 17.6k
Avraham Ben-Tzvi	Independent Director	2.2yrs	US$239.91k	0.36% $ 17.6k
Eric Greenberg	Independent Director	2.2yrs	US$244.07k	0.36% $ 17.6k
Brynner Chiam	Independent Director	less than a year	US$9.38k	データなし
Gim Seow	Independent Chairman of the Board	less than a year	US$9.38k	データなし

2.2yrs

平均在職期間

53yo

平均年齢

経験豊富なボード: TTNPの取締役会は経験豊富ではない ( 1.8年の平均在任期間) ため、新しい取締役会が必要であると考えられます。

Titan Pharmaceuticals マネジメント

マネジメント 基準チェック /04

主要情報

経営陣の近況

Titan Pharmaceuticals, Inc. Announces Resignation of Brian Crowley as Senior Vice President, Finance and Administration, Effective February 2, 2024

High number of new and inexperienced directors

Titan Pharmaceuticals, Inc. Announces Board Resignations

Titan Pharmaceuticals, Inc. Announces Board Changes

Principal Executive Officer recently bought US$56k worth of stock

Titan Pharmaceuticals, Inc. Appoints David E. Lazar as Chief Executive Officer, Effective August 16, 2022

Recent updates

Ke Sdn. Bhd. entered into an agreement to acquire Titan Pharmaceuticals, Inc. (NasdaqCM:TTNP) for $21.6 million in a reverse merger transaction.

Titan Pharmaceuticals, Inc. announced delayed 10-Q filing

Titan Pharmaceuticals, Inc. has withdrawn its Follow-on Equity Offering in the amount of $11 million.

Titan Pharmaceuticals, Inc. Announces Resignation of Brian Crowley as Senior Vice President, Finance and Administration, Effective February 2, 2024

Third quarter 2023 earnings released: US$0.023 loss per share (vs US$0.18 loss in 3Q 2022)

High number of new and inexperienced directors

Titan Pharmaceuticals, Inc. Announces Board Resignations

Titan Pharmaceuticals, Inc. announced that it expects to receive $9.5 million in funding from Sire Group Ltd

Second quarter 2023 earnings released: US$0.11 loss per share (vs US$0.18 loss in 2Q 2022)

Fedson, Inc. entered into an Asset Purchase Agreement to acquire Certain ProNeura Assets of Titan Pharmaceuticals, Inc. (NasdaqCM:TTNP) for $52 million.

Fedson, Inc. entered into an Asset Purchase Agreement to acquire Certain ProNeura Assets of Titan Pharmaceuticals, Inc. (NasdaqCM:TTNP) for $52 million.

Titan Pharmaceuticals, Inc. Announces Board Changes

New major risk - Market cap size

Titan Pharmaceuticals Receives Extension Notice from the Listing Qualifications Department of the Nasdaq Notifying the Company an Additional 180-Day Period, or Until October 2, 2023 to Regain Compliance with Nasdaq Listing Rule 5550(b)(1)

First quarter 2023 earnings released: US$0.11 loss per share (vs US$0.24 loss in 1Q 2022)

Principal Executive Officer recently bought US$56k worth of stock

Titan Pharmaceuticals, Inc. Appoints David E. Lazar as Chief Executive Officer, Effective August 16, 2022

Less than half of directors are independent

Titan Pharmaceuticals, Inc. Announces Management Changes

Less than half of directors are independent

Titan Pharmaceuticals Announces Executive Changes

Second quarter 2022 earnings released: US$0.18 loss per share (vs US$0.17 loss in 2Q 2021)

Activist Investing LLC Provides Information to the Shareholders

Is Titan Pharmaceuticals (NASDAQ:TTNP) In A Good Position To Invest In Growth?

Insider recently bought US$1.7m worth of stock

David E Lazar Sends a Letter to Titan Pharmaceuticals Inc

Titan Pharmaceuticals, Inc. Announces Fda Clearance of Ind Application for Nalmefene Implant

Insider recently bought US$348k worth of stock

First quarter 2022 earnings released: US$0.24 loss per share (vs US$0.28 loss in 1Q 2021)

Titan Pharmaceuticals Receives Non-Compliance Letter from Nasdaq

Insider recently bought US$157k worth of stock

Full year 2021 earnings released: US$0.90 loss per share (vs US$1.96 loss in FY 2020)

Third quarter 2021 earnings released: US$0.19 loss per share (vs US$0.45 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.17 loss per share (vs US$1.47 loss in 2Q 2020)

Titan Pharmaceuticals, Inc. Announces Positive Results from the First Studies of TP-2021 Implant in an Established Animal Model of Chronic Pruritus

First quarter 2021 earnings released: US$0.28 loss per share (vs US$2.03 loss in 1Q 2020)

New 90-day low: US$2.88

Titan Pharmaceuticals, Inc. Announces Positive Early Study Results Help Pave Wave for Titan Pharmaceuticals to Move Forward with Its Jt-09 Proneura® Development Program

Titan Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements

Titan Pharma regains Nasdaq listing compliance

Titan Pharmaceuticals announces 1-for-30 reverse stock split

Titan Pharmaceuticals, Inc., Annual General Meeting, Dec 30, 2020

Titan Pharmaceuticals EPS misses by $0.01, beats on revenue

Titan Pharma closes debt settlement and JT-09 acquisition

Titan Pharmaceuticals, Inc. has completed a Composite Units Offering in the amount of $11.44275 million.

Titan Pharma to raise $8M in stock offering

Titan Pharmaceuticals, Inc. Announces Executive Changes

Titan Pharmaceuticals, Inc. to Report Q3, 2019 Results on Nov 14, 2019

Analysts update estimates

New 90-day low - US$0.27

Earnings released

Titan Pharmaceuticals, Inc. to Report Q2, 2020 Results on Aug 14, 2020